Back to News & Events

IBNY 08 Open Call for Applications

IndieBio NY is hosting an open call for consideration to be a part of its upcoming Spring 2024 Class 08 Cohort. If you are a founder building an early stage pre-seed biotech company that addresses a pressing human and planetary health problem, this may be for you.

Applications can be submitted at the link by January 19th, 2024. Selected companies will be notified as soon as possible and pitches will be scheduled for the first week of February with virtual and in person options available: https://airtable.com/app4sqweetYmYsYct/shrnu4JPt2y86CDtv

IndieBio is the world’s largest seed life sciences development program devoted to funding and building startups to solve humanity’s most pressing problems with life itself. Twice a year, IndieBio selects 10 to 15 early-stage companies across different sectors in the life sciences to partake in an intensive 4-month program in New York City.

Each team is provided with funding, a rent-free lab, co-working space, dedicated educational programming and mentorship, and access to IndieBio’s massive network of alumni, investors, entrepreneurs, press, and corporate partners. Learn more about IndieBio at https://indiebio.co/.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3433 [post_author] => 3 [post_date] => 2020-01-31 19:46:34 [post_date_gmt] => 2020-01-31 19:46:34 [post_content] => BARDA is supporting US government market research to identify medical countermeasures with the potential to help address the 2019 novel coronavirus outbreak. The agency wants to hear from companies developing diagnostics, therapeutics, vaccines, or other products. They are asking for a very brief (500-word) description of the product or technology, accompanied by a quad chart slide and one other short slide deck of your choosing. Please note that while they will use any information you present as market research, submission is no guarantee of funding and your submission will be shared across U.S. Government agencies involved in nCoV countermeasure research and development. Learn More: https://medicalcountermeasures.gov/app/barda/coronavirus.aspx [post_title] => BARDA Seeking Info to Identify Countermeasure to 2019 Novel Coronovirus [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-seeking-info-to-identify-countermeasure-to-2019-novel-coronovirus [to_ping] => [pinged] => [post_modified] => 2020-01-31 19:46:34 [post_modified_gmt] => 2020-01-31 19:46:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3433 [menu_order] => 76 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3422 [post_author] => 3 [post_date] => 2020-01-15 14:35:02 [post_date_gmt] => 2020-01-15 14:35:02 [post_content] => The IndieBio life sciences accelerator has officially launched in New York and is now accepting applications until March 1st. Each team accepted into the program will receive $250K, lab and co-working space and mentorship during the four-month program that kicks off in April 2020. IndieBio is looking for early-stage companies where biology is the underlying technology, which includes therapeutics, devices, diagnostics, computational biology as well as consumer and industrial applications, such as plant-based foods, cellular agriculture. Therapeutics companies accepted into IndieBio New York are eligible to receive up to $2 million. IndieBio, the world’s first life sciences accelerator, was created by venture fund SOSV in 2014. In the past five years, SOSV/IndieBio has backed nearly 200 life science startups with a combined valuation of over $3 billion, raising more than $700 million and employing over 2,000 people. [post_title] => Life Science Accelerator IndieBio Launches in NYC [post_excerpt] => New life science accelerator has launched in New York City, offering space, financing and more. Applications open and accepted until March 1, 2020. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => life-science-accelerator-indiebio-launches-in-nyc [to_ping] => [pinged] => [post_modified] => 2020-01-15 14:35:02 [post_modified_gmt] => 2020-01-15 14:35:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3422 [menu_order] => 78 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3806 [post_author] => 4 [post_date] => 2021-08-17 11:10:50 [post_date_gmt] => 2021-08-17 11:10:50 [post_content] =>

Stony Brook University, College of Business in partnership with the Center for Biotechnology and Department of Biomedical Engineering has been awarded an Empire State Development Life Science Entrepreneur Development grant to address the growing need for entrepreneurial talent in New York’s life science ecosystem. These entrepreneur development grants will help close the talent gap that has previously limited life science commercialization in the state and will develop entrepreneurs with the mix of skills and expertise needed to successfully guide innovative life science startups along the path to commercial viability.

Five graduate schools of business working in collaboration with graduate programs in the life sciences have been awarded grants of up to $500,000 each to implement a new MBA concentration or certificate in life science entrepreneurship. Collaborations between the business school and life science graduate program are critical to equipping students with the skills needed to become leaders in New York’s growing life science ecosystem.

Dr. Clinton Rubin, Director of the Center for Biotechnology commented, “We hope to build from this NYS entrepreneurship education program to train the next generation of bioscience industry leaders. these students are perfectly placed to help lift NYS biotech to the next level, and translate next generation therapeutics, diagnostics and medical devices from the academic to the business sector.”

Read the full Empire State Development press release here.

[post_title] => SBU & CFB Receive Empire State Development Life Science Entrepreneur Development Award [post_excerpt] => Stony Brook University in partnership with the Center for Biotechnology been awarded an Empire State Development Life Science Entrepreneur Development grant to address the growing need for entrepreneurial talent in New York’s life science ecosystem. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sbu-cfb-receive-empire-state-development-life-science-entrepreneur-development-award [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:06:44 [post_modified_gmt] => 2022-12-13 17:06:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3806 [menu_order] => 40 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

BARDA Seeking Info to Identify Countermeasure to 2019 Novel Coronovirus

More Information

Life Science Accelerator IndieBio Launches in NYC

More Information

SBU & CFB Receive Empire State Development Life Science Entrepreneur Development Award

More Information